So far, in vitro and in vivo findings suggested that the GLP-1 receptor agonist Liraglutide decreases hyperglycemia-induced kidney damage by reducing the proliferation of mesangial cells, albuminuria, oxidative stress and inflammatory cytokines [28,29,30] possibly through the alteration of TGF-β expression, but the molecular mechanisms involved in this process have yet to be fully clarified. Here, GLP1R is linked to Hyperglycemia.